The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Characterization of neuroendocrine prostate cancer (NEPC) in patients with metastatic castration resistant prostate cancer (mCRPC) resistant to abiraterone (Abi) or enzalutamide (Enz): Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT).
 
Eric Jay Small
No Relationships to Disclose
 
Jiaoti Huang
No Relationships to Disclose
 
Jack Youngren
Stock and Other Ownership Interests - Triact Therapeutics
 
Artem Sokolov
No Relationships to Disclose
 
Rahul Raj Aggarwal
Research Funding - Janssen-Ortho
 
George Thomas
No Relationships to Disclose
 
Lawrence D. True
Stock and Other Ownership Interests - Pfizer
Research Funding - Ventana Medical Systems
Travel, Accommodations, Expenses - Ventana Medical Systems
 
Li Zhang
No Relationships to Disclose
 
Adam Foye
No Relationships to Disclose
 
Joshi J. Alumkal
Consulting or Advisory Role - Gilead Sciences
Research Funding - Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); ImClone Systems (Inst); Millennium (Inst); Novartis (Inst)
 
Charles J. Ryan
Honoraria - Astellas Pharma; Janssen Oncology
Consulting or Advisory Role - Bayer; Millennium
Research Funding - BIND Biosciences; Karyopharm Therapeutics; Novartis
 
Matthew Rettig
Speakers' Bureau - Janssen Biotech
Research Funding - Astellas Pharma; GlaxoSmithKline; Medivation
 
Christopher P. Evans
Stock and Other Ownership Interests - Medivation; Oncogenex
Honoraria - Janssen Oncology; Medivation; Sanofi
Consulting or Advisory Role - Janssen Oncology; Medivation; Millennium
Speakers' Bureau - Janssen Oncology; Medivation; Sanofi
Research Funding - Medivation
Travel, Accommodations, Expenses - Astellas Pharma; Janssen Oncology; Medivation; Sanofi
 
Martin Edwin Gleave
No Relationships to Disclose
 
Robert Baertsch
No Relationships to Disclose
 
Josh Stuart
No Relationships to Disclose
 
Robert Evan Reiter
No Relationships to Disclose
 
Primo Lara
Honoraria - Pfizer
Consulting or Advisory Role - Astex Pharmaceuticals; Clovis Oncology; Exelixis; Halozyme; Immunogen; Janssen; Lilly; LPath; Medivation; Novartis; Pfizer; Sanofi; Teva; US Diagnostic Services
Research Funding - Aragon Pharmaceuticals (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Heat Biologics (Inst); Janssen Biotech (Inst); Millennium (Inst); Oncogenex (Inst); Polaris (Inst)
 
Kim N. Chi
Honoraria - Astellas Pharma; Janssen; Sanofi
Consulting or Advisory Role - Amgen; Astellas Pharma; Bayer; ESSA; Janssen; Lilly/ImClone; Sanofi; Takeda
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Bayer (Inst); Exelixis (Inst); Janssen (Inst); Novartis (Inst); Oncogenex (Inst); Sanofi (Inst); Teva (Inst); Tokai Pharmaceuticals (Inst)
 
Tomasz M. Beer
Stock and Other Ownership Interests - Salarius Pharmaceuticals
Consulting or Advisory Role - Astellas Pharma; Bayer; Dendreon; Janssen; Novartis; Sotio
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Janssen Research & Development (Inst); Medivation (Inst); OncoGenex (Inst); Sotio (Inst)